…in laymen’s terms what are you predicting or speculating will happen with this condition different from the other three?
GC, sorry, I’m still trying to process all this myself! Perhaps if I reduce this to a few key points.
- We can now have evidence that Neuren, Acadia and Baker Brothers all have some kind of interest in a treatment for Prader-Willi (PW).
- The first to show interest in PW was Baker Brothers (BB) in November 2019. BB invested in and joined the Board of a tiny biotech whose only asset was an investigational treatment for PW.
- Neuren suddenly added the PW indication to its development pipeline in early 2021, almost 2 years after choosing its other 3 indications. I have always had the sense that this late addition of the PW program was driven by outside interest.
- I’m not sure why there have been delays in Neuren commencing the PW trial. Perhaps, as sillazze suggests, we’ll shortly hear that Acadia will join NEU in the development of Prader-Willi? Or perhaps the intention is to allow the other 3 indications to read out first so that, if those studies are a success, their full value would have to be factored in if someone decided to make a move on Neuren post-PW readout.
- The hallmark symptom of hyperphagia (abnormal hunger and excessive eating) is another difference between PW and the other 3 indications. Controlling hyperphagia has been found to be a key goal for PW caregivers. In the preclinical animal testing of NNZ-2591 in PW, at the higher dose, obesity was eliminated and abnormally high insulin levels were reduced to normal (Ref. NEU ASX Ann. 16/02/21). Think about that for a minute.
- Forums
- ASX - By Stock
- NEU
- Ann: Investor Presentation, 14 March 2023
Ann: Investor Presentation, 14 March 2023, page-64
-
- There are more pages in this discussion • 82 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$20.45 |
Change
-0.070(0.34%) |
Mkt cap ! $2.613B |
Open | High | Low | Value | Volume |
$20.60 | $20.77 | $20.32 | $3.866M | 188.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 237 | $20.44 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.49 | 1026 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2633 | 20.380 |
3 | 1467 | 20.360 |
1 | 1033 | 20.350 |
2 | 1853 | 20.340 |
1 | 828 | 20.320 |
Price($) | Vol. | No. |
---|---|---|
20.490 | 1026 | 2 |
20.550 | 2289 | 3 |
20.560 | 639 | 2 |
20.570 | 631 | 3 |
20.590 | 828 | 1 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online